3. Categories

      eCliniqua: eClinical Products, Electronic Data Capture (EDC), Market Insights, Regulatory Issues & Drug Safety, Trial Design and Logistics

  4. About Exelixis

    Exelixis is a genomics-based drug discovery company located in South San Francisco, Ca. It works on the development of anti-cancer therapies. Exelixis has several compounds in various stages of FDA approval and is listed on NASDAQ (EXEL).

  7. SPONSORED LINKS

    Optimize Trial Design through Simulation Modeling - Webinar

    White Paper: Improving Drug Manufacturing Quality with a SDMS

    Exemplar Biomarker Discovery – Your Complete Solution for Personalized Medicine

    Free Webinar - Running Adaptive Clinical Trials: Myth and Reality

    Free Webinar on Compliance and Patient Data –Meeting the Needs!

    Grid Engine @ Univa: 200 improvements and counting

    Analyze, compare & visualize NGS datasets with CLC bio's intuitive platform

    Protect Your Kingdom - RSA Conf 2012

    Free whitepaper: Understanding Legal Issues Surrounding Electronic Lab Notebook Records

    ClearTrial Named a Gartner "Cool Vendor in Life Sciences, 2011"

    Data Repository, ELN, & Laboratory Execution - Waters® NuGenesis® SDMS

    Discover Timaeus 5, an on-demand eClinical platform for Study Design Through Reporting.

    Free WhitePaper: Increase Innovation with Improved Scientific Data Management

    Biotech 2010 Life Sciences: Adapting for Success

    Online community for pioneers in next-gen sequencing & bioinformatics

    Barnett International: Training Strategy and Consulting

    Competitive Analysis & Insight with Concise Research Reports

    Current & Innovative NGS Technologies, Services & Markets

    Next Generation Mass Spectrometry

    New Trends in Preventive and Therapeutic Vaccines

    Next-Generation Sequencing Technologies: Applications and Markets

  1. Exelixis

    0 Comments Leave a Comment

    1-5 of 5

    1. Mentioned In 5 Articles

    2. Flurry Of Cancer Pacts

      Explore Chemical & Engineering News (Jan 3 2012) Market Insights

      ...ront and up to $120 million in milestone payments. In a deal aimed at the same pathway, Merck and Exelixis signed a licensing agreement under which Merck will pay $12 million up front for worldwide rights t... (Read Full Article)

      Comment Mentions:   AstraZeneca   Merck & Co.   Eli Lilly & Co.

    3. Exelixis 2011: Not What the Doctor Ordered

      Explore Fool.com (Dec 27 2011) Electronic Data Capture (EDC)

      ...ment from the FDA. Sitting at half the price it was when the year started, 2011 hasn't been kind to Exelixis ( The year started out well enough, with investors waiting for highly anticipated phase 3 data test... (Read Full Article)

      Comment Mentions:   FDA   AstraZeneca   Dendreon

    4. 3 Biotechs Ready to Move

      Explore Fool.com (Aug 31 2011) Electronic Data Capture (EDC) , Regulatory Issues & Drug Safety , Trial Design and Logistics

      ...re are three biotechs with upcoming events that could drive their value higher. Results, eventually Exelixis ( ) was expecting data for its lead compound, cabozantinib, in medullary thyroid cancer by now, but... (Read Full Article)

      Comment Mentions:   FDA   Novo Nordisk A/S   Amylin Pharmaceuticals

    5. GSK, J&J to trial next-generation malaria vaccine

      Explore reuters.com (Jun 7 2011) Electronic Data Capture (EDC) , Regulatory Issues & Drug Safety , Trial Design and Logistics

      ...al next-generation malaria vaccine * Tweet * * Share this * * Email * Print Related News * UPDATE 4-Exelixis shrs fall on cancer drug safety concerns Mon, Jun 6 2011 * Next up for melanoma treatment: drug coc... (Read Full Article)

      Comment Mentions:   GlaxkSmithKline plc   Johnson & Johnson   Exelixis

    6. 5 Biotechs With Upcoming Clinical Trial Results

      Explore Fool.com (May 31 2011) Electronic Data Capture (EDC) , Regulatory Issues & Drug Safety , Trial Design and Logistics

      ...approvals. Here's a handful of biotechs with upcoming clinical trial results. Little now, big later Exelixis ( ) is expecting phase 3 data for cabozantinib in medullary thyroid cancer shortly. There's little ... (Read Full Article)

      Comment Mentions:   FDA   American Society of Clinical Oncology   Astellas Pharma Inc

    7. 1-5 of 5